Berris van Kessel

2.1k total citations
33 papers, 1.5k citations indexed

About

Berris van Kessel is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Berris van Kessel has authored 33 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 18 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Berris van Kessel's work include Multiple Myeloma Research and Treatments (21 papers), Peptidase Inhibition and Analysis (11 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Berris van Kessel is often cited by papers focused on Multiple Myeloma Research and Treatments (21 papers), Peptidase Inhibition and Analysis (11 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Berris van Kessel collaborates with scholars based in Netherlands, United States and Denmark. Berris van Kessel's co-authors include Tuna Mutis, Niels W.C.J. van de Donk, Henk M. Lokhorst, Andries C. Bloem, Paul W.H.I. Parren, Inger S. Nijhof, Richard W.J. Groen, Joost M. Bakker, H M Lokhorst and Michel de Weers and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Berris van Kessel

30 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Berris van Kessel Netherlands 14 963 793 573 438 335 33 1.5k
Parul Doshi United States 19 745 0.8× 787 1.0× 568 1.0× 454 1.0× 204 0.6× 49 1.6k
Michel de Weers Netherlands 12 1.0k 1.1× 657 0.8× 618 1.1× 720 1.6× 320 1.0× 28 1.7k
Kenneth Wen United States 16 740 0.8× 787 1.0× 570 1.0× 427 1.0× 209 0.6× 52 1.3k
Éric Charpentier United States 15 372 0.4× 652 0.8× 401 0.7× 186 0.4× 142 0.4× 22 1.0k
Tinisha McDonald United States 12 868 0.9× 543 0.7× 753 1.3× 361 0.8× 29 0.1× 30 1.7k
Christina Krupka Germany 13 502 0.5× 861 1.1× 398 0.7× 594 1.4× 198 0.6× 25 1.3k
Vikas A. Gupta United States 17 926 1.0× 641 0.8× 1.0k 1.8× 198 0.5× 63 0.2× 76 1.6k
Homer Adams United States 10 401 0.4× 401 0.5× 249 0.4× 237 0.5× 195 0.6× 25 713
Lilla Cro Italy 19 575 0.6× 472 0.6× 820 1.4× 544 1.2× 159 0.5× 30 1.9k
Gema Mateo Spain 22 1.7k 1.8× 814 1.0× 1.2k 2.1× 308 0.7× 137 0.4× 32 2.2k

Countries citing papers authored by Berris van Kessel

Since Specialization
Citations

This map shows the geographic impact of Berris van Kessel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berris van Kessel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berris van Kessel more than expected).

Fields of papers citing papers by Berris van Kessel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berris van Kessel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berris van Kessel. The network helps show where Berris van Kessel may publish in the future.

Co-authorship network of co-authors of Berris van Kessel

This figure shows the co-authorship network connecting the top 25 collaborators of Berris van Kessel. A scholar is included among the top collaborators of Berris van Kessel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Berris van Kessel. Berris van Kessel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Frerichs, Kristine A., Marloes E.C. Broekmans, Berris van Kessel, et al.. (2020). Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clinical Cancer Research. 26(9). 2203–2215. 68 indexed citations
2.
Oostindie, Simone C., Hilma J. van der Horst, Laurens P. Kil, et al.. (2020). DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer Journal. 10(3). 30–30. 49 indexed citations
3.
Krejcik, Jakub, Inger S. Nijhof, Berris van Kessel, et al.. (2017). Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research. 23(24). 7498–7511. 119 indexed citations
4.
Nijhof, Inger S., Tineke Casneuf, Berris van Kessel, et al.. (2016). CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 128(7). 959–970. 275 indexed citations
5.
Nijhof, Inger S., Richard W.J. Groen, H M Lokhorst, et al.. (2015). Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 29(10). 2039–2049. 203 indexed citations
6.
Bueren, Jeroen J. Lammerts van, Berris van Kessel, Pascale André, et al.. (2014). Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 100(2). 263–268. 89 indexed citations
7.
Nijhof, Inger S., Sonja Zweegman, Mark‐David Levin, et al.. (2013). Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study). Blood. 122(21). 287–287. 1 indexed citations
8.
9.
10.
Weers, Michel de, Berris van Kessel, Joost M. Bakker, et al.. (2011). The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro. Blood. 118(21). 5106–5106.
11.
Veer, Michael S. van der, Michel de Weers, Berris van Kessel, et al.. (2011). The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer Journal. 1(10). e41–e41. 81 indexed citations
12.
Groen, Richard W.J., Frans M.A. Hofhuis, Berris van Kessel, et al.. (2010). In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma. Blood. 116(21). 3058–3058. 3 indexed citations
13.
Veer, Michael S. van der, Michel de Weers, Berris van Kessel, et al.. (2010). Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib. Blood. 116(21). 3030–3030. 2 indexed citations
14.
Veer, Michael S. van der, Michel de Weers, Berris van Kessel, et al.. (2010). Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 96(2). 284–290. 168 indexed citations
15.
Groen, Richard W.J., Frans M.A. Hofhuis, Berris van Kessel, et al.. (2010). A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing. Blood. 116(21). 981–981. 1 indexed citations
16.
Spek, Ellen van der, et al.. (2008). Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leukemia Research. 33(1). 100–108. 20 indexed citations
17.
Spek, Ellen van der, et al.. (2007). Lenalidomide synergizes with simvastatin in myeloma. Haematologica. 92(6). 151–152.
18.
Eurelings, M., Henk M. Lokhorst, Nicolette C. Notermans, et al.. (2007). Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy. Journal of the Neurological Sciences. 260(1-2). 124–131. 2 indexed citations
19.
Eurelings, M., Nicolette C. Notermans, Henk M. Lokhorst, et al.. (2006). Immunoglobulin gene analysis in polyneuropathy associated with IgM monoclonal gammopathy. Journal of Neuroimmunology. 175(1-2). 152–159. 2 indexed citations
20.
Bloem, Andries C., et al.. (2002). Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38– haematopoietic stem cells. British Journal of Haematology. 117(1). 226–237. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Parul Doshi Breakdown of academic impact, for papers by Michel de Weers Breakdown of academic impact, for papers by Kenneth Wen Breakdown of academic impact, for papers by Éric Charpentier Breakdown of academic impact, for papers by Tinisha McDonald Breakdown of academic impact, for papers by Christina Krupka Breakdown of academic impact, for papers by Vikas A. Gupta Breakdown of academic impact, for papers by Homer Adams Breakdown of academic impact, for papers by Lilla Cro Breakdown of academic impact, for papers by Gema Mateo
Rankless by CCL
2026